Keywords
Last Name
Institution

Grover Miller

TitleAssociate Professor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentBiochemistry & Molecular Biology, College of Medicine
DivisionBiochemistry & Molecular Xenobiotic
AddressB421A Biomedical Research I
325 S. Elm St.
Mail Slot # 516
Little Rock AR 72205
Phone501-526-6486
vCardDownload vCard
    Other Positions
    TitleAssociate Professor
    InstitutionUniversity of Arkansas for Medical Sciences
    DepartmentBiomedical Informatics, College of Medicine


    Collapse Research Funds 

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Dang NL, Hughes TB, Miller GP, Swamidass SJ. Computational Approach to Structural Alerts: Furans, Phenols, Nitroaromatics, and Thiophenes. Chem Res Toxicol. 2017 Apr 17; 30(4):1046-1059. PMID: 28256829.
      View in: PubMed
    2. Hartman JH, Miller GP, Caro AA, Byrum SD, Orr LM, Mackintosh SG, Tackett AJ, MacMillan-Crow LA, Hallberg LM, Ameredes BT, Boysen G. 1,3-Butadiene-induced mitochondrial dysfunction is correlated with mitochondrial CYP2E1 activity in Collaborative Cross mice. Toxicology. 2017 Mar 01; 378:114-124. PMID: 28082109.
      View in: PubMed
    3. Bostian AC, Maddukuri L, Reed MR, Savenka T, Hartman JH, Davis L, Pouncey DL, Miller GP, Eoff RL. Kynurenine Signaling Increases DNA Polymerase Kappa Expression and Promotes Genomic Instability in Glioblastoma Cells. Chem Res Toxicol. 2016 Jan 19; 29(1):101-8. PMID: 26651356; PMCID: PMC4718841 [Available on 01/19/17].
    4. Hartman JH, Martin HC, Caro AA, Pearce AR, Miller GP. Subcellular localization of rat CYP2E1 impacts metabolic efficiency toward common substrates. Toxicology. 2015 Dec 02; 338:47-58. PMID: 26463279; PMCID: PMC4658230 [Available on 12/02/16].
    5. Hartman JH, Letzig LG, Roberts DW, James LP, Fifer EK, Miller GP. Cooperativity in CYP2E1 metabolism of acetaminophen and styrene mixtures. Biochem Pharmacol. 2015 Oct 01; 97(3):341-9. PMID: 26225832.
      View in: PubMed
    6. Hughes TB, Miller GP, Swamidass SJ. Site of reactivity models predict molecular reactivity of diverse chemicals with glutathione. Chem Res Toxicol. 2015 Apr 20; 28(4):797-809. PMID: 25742281.
      View in: PubMed
    7. Levy JW, Hartman JH, Perry MD, Miller GP. Structural basis for cooperative binding of azoles to CYP2E1 as interpreted through guided molecular dynamics simulations. J Mol Graph Model. 2015 Mar; 56:43-52. PMID: 25544389; PMCID: PMC4314338.
    8. Pugh CP, Pouncey DL, Hartman JH, Nshimiyimana R, Desrochers LP, Goodwin TE, Boysen G, Miller GP. Multiple UDP-glucuronosyltransferases in human liver microsomes glucuronidate both R- and S-7-hydroxywarfarin into two metabolites. Arch Biochem Biophys. 2014 Dec 15; 564:244-53. PMID: 25447818; PMCID: PMC4258421.
    9. Hartman JH, Miller GP, Boysen G. Inhibitory potency of 4-carbon alkanes and alkenes toward CYP2E1 activity. Toxicology. 2014 Apr 06; 318:51-8. PMID: 24561005; PMCID: PMC4747242.
    10. Hartman JH, Knott K, Miller GP. CYP2E1 hydroxylation of aniline involves negative cooperativity. Biochem Pharmacol. 2014 Feb 01; 87(3):523-33. PMID: 24345333.
      View in: PubMed
    11. Pianalto KM, Hartman JH, Boysen G, Miller GP. Differences in butadiene adduct formation between rats and mice not due to selective inhibition of CYP2E1 by butadiene metabolites. Toxicol Lett. 2013 Nov 25; 223(2):221-7. PMID: 24021170; PMCID: PMC3831829.
    12. Hartman JH, Bradley AM, Laddusaw RM, Perry MD, Miller GP. Structure of pyrazole derivatives impact their affinity, stoichiometry, and cooperative interactions for CYP2E1 complexes. Arch Biochem Biophys. 2013 Sep 01; 537(1):12-20. PMID: 23811196; PMCID: PMC3781954.
    13. Hartman JH, Cothren SD, Park SH, Yun CH, Darsey JA, Miller GP. Predicting CYP2C19 catalytic parameters for enantioselective oxidations using artificial neural networks and a chirality code. Bioorg Med Chem. 2013 Jul 01; 21(13):3749-59. PMID: 23673224; PMCID: PMC3674096.
    14. Hartman JH, Boysen G, Miller GP. Cooperative effects for CYP2E1 differ between styrene and its metabolites. Xenobiotica. 2013 Sep; 43(9):755-64. PMID: 23327532; PMCID: PMC3979932.
    15. Kim SY, Kang JY, Hartman JH, Park SH, Jones DR, Yun CH, Boysen G, Miller GP. Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. Drug Metab Lett. 2012 Sep 01; 6(3):157-64. PMID: 23331088; PMCID: PMC3713490.
    16. Hartman JH, Boysen G, Miller GP. CYP2E1 metabolism of styrene involves allostery. Drug Metab Dispos. 2012 Oct; 40(10):1976-83. PMID: 22807108; PMCID: PMC3463823.
    17. Freyaldenhoven S, Li Y, Kocabas AM, Ziu E, Ucer S, Ramanagoudr-Bhojappa R, Miller GP, Kilic F. The role of ERp44 in maturation of serotonin transporter protein. J Biol Chem. 2012 May 18; 287(21):17801-11. PMID: 22451649; PMCID: PMC3366855.
    18. Freyaldenhoven, S, Li, Y, Kocabas, AM, Ziu, E, Ucer, S, Ramanagoudr-Bhojappa, R, Miller GP, Kilic, F. The Role of ERp44 on Maturation of Serotonin Transporter Proteins. J Biol Chem. 2012; 287:17801-11.
    19. Jones DR, Miller GP. Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know. Expert Opin Drug Metab Toxicol. 2011 Jul; 7(7):857-74. PMID: 21480820.
      View in: PubMed
    20. Jones DR, Boysen G, Miller GP. Novel multi-mode ultra performance liquid chromatography-tandem mass spectrometry assay for profiling enantiomeric hydroxywarfarins and warfarin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 May 01; 879(15-16):1056-62. PMID: 21470921.
      View in: PubMed
    21. Jones, DR, Boysen, G, Miller GP. Novel Dual-Phase Ultra Performance Liquid Chromatography-Tandem Mass Spectrometry Assay for Profiling Enantiomeric Hydroxywarfarins and Warfarin in Human Plasma. J Chromatogr B. 2011; 879:1056-62.
    22. Jones DR, Kim SY, Boysen G, Yun CH, Miller GP. Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin. Drug Metab Lett. 2010 Dec; 4(4):213-9. PMID: 20615193.
      View in: PubMed
    23. Jones DR, Kim SY, Guderyon M, Yun CH, Moran JH, Miller GP. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin. Chem Res Toxicol. 2010 May 17; 23(5):939-45. PMID: 20429590.
      View in: PubMed
    24. Jang HH, Jamakhandi AP, Sullivan SZ, Yun CH, Hollenberg PF, Miller GP. Beta sheet 2-alpha helix C loop of cytochrome P450 reductase serves as a docking site for redox partners. Biochim Biophys Acta. 2010 Jun; 1804(6):1285-93. PMID: 20152939; PMCID: PMC2847005.
    25. Jones DR, Moran JH, Miller GP. Warfarin and UDP-glucuronosyltransferases: writing a new chapter of metabolism. Drug Metab Rev. 2010 Feb; 42(1):55-61. PMID: 19788348.
      View in: PubMed
    26. William L., Miller GP. Chemistry Demystified. McGraw-Hill Companies, Inc. 2010.
    27. Miller GP, Jones DR, Sullivan SZ, Mazur A, Owen SN, Mitchell NC, Radominska-Pandya A, Moran JH. Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chem Res Toxicol. 2009 Jul; 22(7):1239-45. PMID: 19408964; PMCID: PMC2819755.
    28. Mazur A, Lichti CF, Prather PL, Zielinska AK, Bratton SM, Gallus-Zawada A, Finel M, Miller GP, Radominska-Pandya A, Moran JH. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos. 2009 Jul; 37(7):1496-504. PMID: 19339377; PMCID: PMC2698943.
    29. Mazur, A, Lichti, CF, Prather, P, Zielinska, AK, Bratton, SM, Gallus-Zawada, A, Finel, M, Miller, GP, Radominska-Pandya, A, Moran, JH. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase (UGTs) enzymes involved in the metabolism of classical cannabinoids. Drug Metab Dispo. 2009; 37:1496-504.
    30. Miller GP, Lichti CF, Zielinska AK, Mazur A, Bratton SM, Gallus-Zawada A, Finel M, Moran JH, Radominska-Pandya A. Identification of hydroxywarfarin binding site in human UDP glucuronosyltransferase 1a10: phenylalanine90 is crucial for the glucuronidation of 6- and 7-hydroxywarfarin but not 8-hydroxywarfarin. Drug Metab Dispos. 2008 Nov; 36(11):2211-8. PMID: 18725508; PMCID: PMC2812427.
    31. Miller GP. Advances in the interpretation and prediction of CYP2E1 metabolism from a biochemical perspective. Expert Opin Drug Metab Toxicol. 2008 Aug; 4(8):1053-64. PMID: 18680440.
      View in: PubMed
    32. Miller, GP, Lichti, CF, Zielinska, AK, Bratton, SM, Mazur, A, Gallus-Zawada, A, Finel, M, Moran, JH, Radominska-Pandya, A. Identification of hydroxywarfarin binding site in human UGT1A10: Phenylalanine90 is crucial for the glucuronidation of 6- and 7-hydroxy- but not 8-hydroxywarfarin. Drug Metab Dispo. 2008; 36:2211-8.
    33. Collom SL, Laddusaw RM, Burch AM, Kuzmic P, Perry MD, Miller GP. CYP2E1 substrate inhibition. Mechanistic interpretation through an effector site for monocyclic compounds. J Biol Chem. 2008 Feb 08; 283(6):3487-96. PMID: 18056994; PMCID: PMC3933162.
    34. Xiong Y, Patana AS, Miley MJ, Zielinska AK, Bratton SM, Miller GP, Goldman A, Finel M, Redinbo MR, Radominska-Pandya A. The first aspartic acid of the DQxD motif for human UDP-glucuronosyltransferase 1A10 interacts with UDP-glucuronic acid during catalysis. Drug Metab Dispos. 2008 Mar; 36(3):517-22. PMID: 18048489; PMCID: PMC2275115.
    35. Zielinska A, Lichti CF, Bratton S, Mitchell NC, Gallus-Zawada A, Le VH, Finel M, Miller GP, Radominska-Pandya A, Moran JH. Glucuronidation of monohydroxylated warfarin metabolites by human liver microsomes and human recombinant UDP-glucuronosyltransferases. J Pharmacol Exp Ther. 2008 Jan; 324(1):139-48. PMID: 17921187; PMCID: PMC2275122.
    36. Jamakhandi AP, Kuzmic P, Sanders DE, Miller GP. Global analysis of protein-protein interactions reveals multiple CYP2E1-reductase complexes. Biochemistry. 2007 Sep 04; 46(35):10192-201. PMID: 17685587; PMCID: PMC2592557.
    37. Jamakhandi, AP, Kuzmic, P, Sanders, DA, Miller G. Global Analysis of Protein-Protein Interactions Reveals Multiple Cytochrome P450 2E1-Reductase Complexes. Biochemistry. 2007; 46:10192-201.
    38. Collom SL, Jamakhandi AP, Tackett AJ, Radominska-Pandya A, Miller GP. CYP2E1 active site residues in substrate recognition sequence 5 identified by photoaffinity labeling and homology modeling. Arch Biochem Biophys. 2007 Mar 01; 459(1):59-69. PMID: 17222385; PMCID: PMC1994253.
    39. Jamakhandi AP, Jeffus BC, Dass VR, Miller GP. Thermal inactivation of the reductase domain of cytochrome P450 BM3. Arch Biochem Biophys. 2005 Jul 15; 439(2):165-74. PMID: 15950923; PMCID: PMC3664205.
    40. Guengerich FP, Miller GP, Hanna IH, Martin MV, L├ęger S, Black C, Chauret N, Silva JM, Trimble LA, Yergey JA, Nicoll-Griffith DA. Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding. Biochemistry. 2002 Sep 10; 41(36):11025-34. PMID: 12206675.
      View in: PubMed
    41. Guengerich FP, Miller GP, Hanna IH, Sato H, Martin MV. Oxidation of methoxyphenethylamines by cytochrome P450 2D6. Analysis of rate-limiting steps. J Biol Chem. 2002 Sep 13; 277(37):33711-9. PMID: 12093814.
      View in: PubMed
    42. Guengerich, FP, Miller G, Hanna, IH, Leger, S, Black, C, Chauret, N, Silva, JM, Trimble, L, Yergey, JA, Nicoll-Griffith, D. Diversity in the Oxidation of Substrates by Cytochrome P450 2D6: Lack of a role of aspartate 301-substrate electrostatic bonding. Biochemistry. 2002; 41:11025-34.
    43. Guengerich, FP, Miller G, Hanna, IH, Sato, H, Martin, MV. Oxidation of Methoxyphenethylamines by Cytochrome P450 2D6: Analysis of rate-limiting steps. J Biol Chem. 2002; 277:33711-19.
    44. Yun, CH, Miller G, Guengerich, FP. Oxidation of p-alkyoxyacylanilides Catalyzed by Human Cytochrome P450 1A2. Biochemistry. 2001; 40:4521-30.
    45. Miller G, Hanna, IH, Nishimura, Y, Guengerich, FP. Oxidation of Phenethylamine Derivative by Cytochrome P450 2D6: The issue of substrate protonation in binding and catalysis. Biochemistry. 2001; 40:14215-23.
    46. Miller G, Wahnon, DC, Benkovic, SJ. Investigating the Importance of Interloop Contacts during Catalysis by Escherichia coli Dihydrofolate Reductase. Biochemistry. 2001; 40:867-75.
    47. Miller G. Binding and Oxidation of Alkyl 4-Nitrophenyl Ethers by Rabbit Cytochrome P450 1A2: Evidence for two binding sites. Biochemistry. 2001; 40:4762-72.
    48. Hosea, NA, Miller G, Guengerich, FP. Elucidation of Distinct Binding Sites for Chtochrome P450 3A4. Biochemistry. 2000; 39:5929-39.
    49. Yun, CH, Miller G, Guengerich, FP. Rate-determining Steps in Phenacetin Oxidations by Human Cytochrome P450 1A2 and Selected Mutants. Biochemistry. 2000; 39:11319-29.
    50. Miller G, Benkovic, SJ. Deletion of a Highly Motional Residue Affects the Formation of the Michaelis Complex for Escherichia coli Dihyrofolate Reductase. Biochemistry,. 1998; 37,:6327-35.
    51. Miller G, Benkovic, S.J. Stretching Exercises--Flexibility in dihydrofolate reductase catalysis. Chemistry and Biology. 1998; 5:R105-13.
    52. Miller G, Benkovic, SJ. Strength of an Interloop Hydrogen Bond Determines the Kinetic Pathway in Catalysis by Escherichia coli Dihydrofolate Reductase. Biochemistry. 1998; 37:6336-42.
    53. Miller G, Posner, BA, Benkovic, SJ. Expanding the 43C9 Class of Catalytic Antibodies using a Chain-shuffling Approach. Bioorg Med Chem. 1997; 5:581-90.
    54. Miller G, Zhong, W., Smiley, J.A., Benkovic, S.J. Combinatorial Approaches to Drug Discovery. Combinatorial Libraries of Peptides, Proteins, and Antibodies using Biological Systems. 1997.
    55. Liotta, LJ, Miller G, Benkovic, PA. A Catalytic Antibody for Imide Hydrolysis Featuring a Bifunctional Transition-state Mimic. J Am Chem Soc. 1993; 115:350-1.
    Miller's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _